218 related articles for article (PubMed ID: 36958842)
1. Diagnosis and management of neuroendocrine tumours.
Cuthbertson DJ; Shankland R; Srirajaskanthan R
Clin Med (Lond); 2023 Mar; 23(2):119-124. PubMed ID: 36958842
[TBL] [Abstract][Full Text] [Related]
2. Multidisciplinary management of refractory insulinomas.
Brown E; Watkin D; Evans J; Yip V; Cuthbertson DJ
Clin Endocrinol (Oxf); 2018 May; 88(5):615-624. PubMed ID: 29205458
[TBL] [Abstract][Full Text] [Related]
3. Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine Tumours.
Dawod M; Gordoa TA; Cives M; De Mestier L; Crona J; Spada F; Oberg K; Pavel M; Lamarca A
Curr Treat Options Oncol; 2021 Jun; 22(8):73. PubMed ID: 34185197
[TBL] [Abstract][Full Text] [Related]
4. Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies.
Ito T; Lee L; Jensen RT
Expert Opin Pharmacother; 2016 Nov; 17(16):2191-2205. PubMed ID: 27635672
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacologic therapy for neuroendocrine tumours].
Petrányi A; Bodoky G
Orv Hetil; 2011 Mar; 152(10):379-91. PubMed ID: 21354954
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
Stueven AK; Kayser A; Wetz C; Amthauer H; Wree A; Tacke F; Wiedenmann B; Roderburg C; Jann H
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234481
[TBL] [Abstract][Full Text] [Related]
7. [Drug therapy for neuroendocrine tumours].
Tóth M
Orv Hetil; 2013 Sep; 154(39):1556-64. PubMed ID: 24058101
[TBL] [Abstract][Full Text] [Related]
8. New treatment strategies in advanced neuroendocrine tumours.
Walter T; Brixi-Benmansour H; Lombard-Bohas C; Cadiot G
Dig Liver Dis; 2012 Feb; 44(2):95-105. PubMed ID: 21983252
[TBL] [Abstract][Full Text] [Related]
9. Advances in the Diagnosis and Management of Well-Differentiated and Intermediate-Differentiated Neuroendocrine Tumors of the Lung.
Wolin EM
Chest; 2017 May; 151(5):1141-1146. PubMed ID: 27373769
[TBL] [Abstract][Full Text] [Related]
10. Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas.
Fazio N; Cinieri S; Lorizzo K; Squadroni M; Orlando L; Spada F; Maiello E; Bodei L; Paganelli G; Delle Fave G; de Braud F
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S87-94. PubMed ID: 21129617
[TBL] [Abstract][Full Text] [Related]
11. Neuroendocrine neoplasms of the small intestine and the appendix - update of the diagnostic and therapeutic guidelines (recommended by the Polish Network of Neuroendocrine Tumours) [Nowotwory neuroendokrynne jelita cienkiego i wyrostka robaczkowego - uaktualnione zasady diagnostyki i leczenia (rekomendowane przez Polską Sieć Guzów Neuroendokrynnych)].
Bednarczuk T; Zemczak A; Bolanowski M; Borowska M; Chmielik E; Ćwikła JB; Foltyn W; Gisterek I; Handkiewicz-Junak D; Hubalewska-Dydejczyk A; Jarząb M; Junik R; Kajdaniuk D; Kamiński G; Kolasińska-Ćwikła A; Kopacz-Wróbel K; Kowalska A; Królicki L; Kunikowska J; Kuśnierz K; Lewiński A; Liszka Ł; Londzin-Olesik M; Marek B; Malczewska A; Nasierowska-Guttmejer A; Nowakowska-Duława E; Pavel ME; Pilch-Kowalczyk J; Reguła J; Rosiek V; Ruchała M; Rydzewska G; Siemińska L; Sowa-Staszczak A; Starzyńska T; Stojčev Z; Strzelczyk J; Studniarek M; Syrenicz A; Szczepkowski M; Wachuła E; Zajęcki W; Zgliczyński W; Zieniewicz K; Kos-Kudła B
Endokrynol Pol; 2022; 73(3):549-583. PubMed ID: 36059174
[TBL] [Abstract][Full Text] [Related]
12. Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours.
Van Essen M; Krenning EP; De Jong M; Valkema R; Kwekkeboom DJ
Acta Oncol; 2007; 46(6):723-34. PubMed ID: 17653893
[TBL] [Abstract][Full Text] [Related]
13. Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective.
Kolasińska-Ćwikła A; Łowczak A; Maciejkiewicz KM; Ćwikła JB
Nucl Med Rev Cent East Eur; 2018; 21(2):. PubMed ID: 29741203
[TBL] [Abstract][Full Text] [Related]
14. The role of somatostatin analogues in the treatment of neuroendocrine tumours.
Grozinsky-Glasberg S; Grossman AB; Korbonits M
Mol Cell Endocrinol; 2008 May; 286(1-2):238-50. PubMed ID: 18037561
[TBL] [Abstract][Full Text] [Related]
15. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives.
Appetecchia M; Baldelli R
J Exp Clin Cancer Res; 2010 Mar; 29(1):19. PubMed ID: 20196864
[TBL] [Abstract][Full Text] [Related]
16. Management of pulmonary neuroendocrine tumors.
Ramirez RA; Chauhan A; Gimenez J; Thomas KEH; Kokodis I; Voros BA
Rev Endocr Metab Disord; 2017 Dec; 18(4):433-442. PubMed ID: 28868578
[TBL] [Abstract][Full Text] [Related]
17. Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.
Del Rivero J; Perez K; Kennedy EB; Mittra ES; Vijayvergia N; Arshad J; Basu S; Chauhan A; Dasari AN; Bellizzi AM; Gangi A; Grady E; Howe JR; Ivanidze J; Lewis M; Mailman J; Raj N; Soares HP; Soulen MC; White SB; Chan JA; Kunz PL; Singh S; Halfdanarson TR; Strosberg JR; Bergsland EK
J Clin Oncol; 2023 Nov; 41(32):5049-5067. PubMed ID: 37774329
[TBL] [Abstract][Full Text] [Related]
18. Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors.
Narayanan S; Kunz PL
Hematol Oncol Clin North Am; 2016 Feb; 30(1):163-77. PubMed ID: 26614375
[TBL] [Abstract][Full Text] [Related]
19. Pancreatic neuroendocrine neoplasms.
Hörsch D; Bert T; Schrader J; Hommann M; Kaemmerer D; Petrovitch A; Zaknun J; Baum RP
Minerva Gastroenterol Dietol; 2012 Dec; 58(4):401-26. PubMed ID: 23207615
[TBL] [Abstract][Full Text] [Related]
20. Peptide Receptor Radionuclide Therapy for Patients With Advanced Lung Carcinoids.
Naraev BG; Ramirez RA; Kendi AT; Halfdanarson TR
Clin Lung Cancer; 2019 May; 20(3):e376-e392. PubMed ID: 30910575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
